PMID- 16556690
OWN - NLM
STAT- MEDLINE
DCOM- 20060707
LR  - 20221207
IS  - 1073-449X (Print)
IS  - 1073-449X (Linking)
VI  - 173
IP  - 11
DP  - 2006 Jun 1
TI  - Dissociation of lung function changes with humoral immunity during inhaled human 
      insulin therapy.
PG  - 1194-200
AB  - RATIONALE: Inhaled human insulin (INH; Exubera [human insulin (recombinant DNA 
      origin) Inhalation Powder]) causes small changes in pulmonary function and 
      increases in insulin antibodies compared with subcutaneous (SC) insulin. 
      OBJECTIVES: To investigate the relationship between changes in pulmonary function 
      and insulin antibodies and acute effects of INH on lung function. METHODS: In a 
      24-wk multicenter study, 226 patients with type 1 diabetes were randomized to 
      receive daily premeal INH or SC insulin for 12 wk (comparative phase), followed 
      by SC insulin for 12 wk (washout phase). MEASUREMENTS: Spirometry tests were 
      conducted and insulin antibody levels were measured throughout the study. Acute 
      insulin-induced changes in lung function were calculated as the difference 
      between FEV1 before, and 10 and 60 min after, insulin. MAIN RESULTS: There was a 
      temporal dissociation between pulmonary function changes and insulin antibody 
      generation. Small treatment group differences in changes in FEV1 from baseline, 
      favoring SC insulin, were fully manifest by 2 wk of INH therapy, did not increase 
      during the remainder of the comparative phase, and resolved within 2 wk of INH 
      discontinuation. By contrast, insulin antibody levels remained low for the first 
      2 wk with INH, increased during Weeks 2 to 12, and gradually declined during 
      washout. There was no evidence of acute insulin-induced alterations in lung 
      function 10 and 60 min postinhalation. CONCLUSION: The small lung function 
      changes observed with INH therapy are not mediated by the humoral immune 
      response, or associated with acute decrements in lung function immediately after 
      insulin inhalation.
FAU - Teeter, John G
AU  - Teeter JG
AD  - Pfizer Global Research and Development, New London, CT 06320, USA. 
      john.g.teeter@pfizer.com
FAU - Riese, Richard J
AU  - Riese RJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20060323
PL  - United States
TA  - Am J Respir Crit Care Med
JT  - American journal of respiratory and critical care medicine
JID - 9421642
RN  - 0 (Exubera)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Insulin Antibodies)
SB  - IM
MH  - Administration, Inhalation
MH  - Adult
MH  - Aged
MH  - Diabetes Mellitus, Type 1/*drug therapy/physiopathology
MH  - Female
MH  - Forced Expiratory Volume/*drug effects
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/*therapeutic use
MH  - Injections, Subcutaneous
MH  - Insulin/administration & dosage/*therapeutic use
MH  - Insulin Antibodies/*blood
MH  - Male
MH  - Middle Aged
MH  - Respiratory Function Tests
EDAT- 2006/03/25 09:00
MHDA- 2006/07/11 09:00
CRDT- 2006/03/25 09:00
PHST- 2006/03/25 09:00 [pubmed]
PHST- 2006/07/11 09:00 [medline]
PHST- 2006/03/25 09:00 [entrez]
AID - 200512-1861OC [pii]
AID - 10.1164/rccm.200512-1861OC [doi]
PST - ppublish
SO  - Am J Respir Crit Care Med. 2006 Jun 1;173(11):1194-200. doi: 
      10.1164/rccm.200512-1861OC. Epub 2006 Mar 23.